Figure S5: Targeted radioligand therapy with [225Ac]Ac-DOTA-YS5 demonstrates high treatment efficacy in the MM.1S subcutaneous MM model.
No takes yet. Share an insight, caveat, or question.
Wadhwa et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: